Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Trending in China – Clothing Company Picks Fight With Shaolin Kung Fu Monastery
Trending in China: Medical Drama Salutes Pandemic Heroes but Stirs Sexism Debate
Trending in China – Can Universities Stop Students Wasting Food And Keep Them Happy?
Alibaba Unveils Delivery Robot to Meet ‘Last-Mile’ Demand
Alibaba Launches Palm-Sized Cloud Computer With ‘Almost Unlimited Computing Resources’
China’s National Science Academy Vows to Close Tech Gaps in 10 Years
Trump’s WeChat Ban May Face Temporary Halt by U.S. Judge
Tencent Clinches Deal to Show England’s Premier League in China
Alibaba Unveils ‘Digital Factory’ as Part of Its ‘New Manufacturing’ Strategy
Trending in China: Basketballer Jeremy Lin - Dream Chaser or Delusional? Netizens Divided as Star Leaves CBA for NBA
Trending in China – The Case of the ‘Missing’ iPhone12
Kuaishou Logs 500 Million Online Shopping Orders in August
U.S.-Listed Chinese Delivery Firm ZTO Express Plans to Raise Up to $1.6 Billion in Hong Kong Secondary Listing
Xiaomi Vice Chairman Promises Not Sell More Stock After Selling Over $1 Billion in Company Shares
Autohome Plans $1 Billion Hong Kong Second Listing
Video Streamer iQiyi Kicks Up Its Sports Game with FC Barcelona Tie-Up
Global First as Potential Nasal Spray Covid-19 Vaccine Proceeds to Clinical Trial Phase
JD.com’s Fintech Unit Plans to Spend $230 Million to Get Second Payment License
Trending in China – A Fight Over Steamed Buns Causes Netizens to Ask Whether Traditional Brands Can Survive in the Modern Era
Loss Making Evergrande’s Electric Vehicle Subsidiary to Raise $516 Million from Investors Including Tencent
Chinese Alzheimer’s Drug to Launch Global Trials Amid Skepticism

By Bloomberg / Dec 30, 2019 10:20 AM / World

picture

picture

A newly approved Chinese drug for Alzheimer’s will start clinical trials in the U.S. and Europe next year as the country’s first novel therapy for the incurable disease seeks global legitimacy.

Shanghai Green Valley Pharmaceutical plans to recruit around 2,046 patients with mild-to-moderate Alzheimer’s for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company’s Vice President Li Jinhe said on Sunday.

The drug, called Oligomannate, was granted conditional approval in China last month. It comes in a 150mg capsule and went on sale in the country on Dec. 29. Patients will need take three capsules twice a day, according to the drug’s package insert. A week’s treatment costs 895 yuan ($128).

In Chinese trials, the drug had statistically improved cognitive function in patients suffering from mild-to-moderate Alzheimer’s as early as week four, Green Valley said in a November statement. Its success, however, has been met with skepticism from Alzheimer’s researchers, who say that details are scant on its clinical trials in China.

“It’s totally understandable for our drug to be questioned,” said Green Valley Chairman Lyu Songtao. “We are confident because we see clear benefits from patients in the clinical trials.”

The conditional approval requires the drugmaker to conduct further studies on how the drug works and its long-term safety and efficacy. The company also said it plans to invest $3 billion in the next 10 years for such investigations -- including on global trials -- to understand its working mechanism and expand its use in treating diseases such as Parkinson’s and vascular dementia.

Related: Questions Swirl Around China’s New Alzheimer’s Drug


Share this article
Open WeChat and scan the QR code